⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223980 | 1.00 | — | — | |
| SCHEMBL10184350 | 0.84 | — | — | |
| SCHEMBL14198062 | 0.82 | — | — | |
| SCHEMBL10184353 | 0.76 | — | — | |
| SCHEMBL13261554 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL29091002 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL29090995 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL26600716 | 0.74 | — | — | |
| SCHEMBL11917816 | 0.71 | — | — | |
| SCHEMBL240784 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240393298-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | PHENOMENEX, INC. (US) | 2024-11-28 | — | — | US | claimed |
| EP-4359786-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | Phenomenex, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| WO-2022271853-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | PHENOMENEX, INC. (US) | 2022-12-29 | — | — | WO | claimed |
| US-20240393298-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | PHENOMENEX, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4359786-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | Phenomenex, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022271853-A1 | MASS SPECTROMETRY-COMPATIBLE PH GRADIENT BUFFER SYSTEM | PHENOMENEX, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| US-20160194320-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2016-07-07 | — | — | US | disclosed |
| US-9266855-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-02-23 | — | — | US | disclosed |
| US-20160016932-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20120077840-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| EP-1557168-B1 | Biarylurea Derivatives | MSD KK (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |